Drug Profile
Research programme: respiratory disease therapeutics - Neurim Pharmaceuticals
Alternative Names: Neu-105; Neu-164Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Neurim Pharmaceuticals
- Class Small molecules
- Mechanism of Action 5-lipoxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Asthma in Israel (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in Israel (PO)
- 28 Oct 2008 Preclinical trials in Asthma in Israel (PO)